Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor β1

Journal of Rheumatology

Volumn 23, Issue 2, 1996, Pages 294-296

  Giacomelli, Roberto ^a,c   Cipriani, Paola ^a   Danese, Chiara ^b   Pizzuto, Pranco ^a   Lattanzio, Rita ^a   Parzanese, Ida ^a   Passacantando, Anna ^a   Perego, Maria Alessandra ^b   Tonietti, Giorgio ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

IL 6; Lymphocyte; Systemic sclerosis; TGF

Indexed keywords

INTERLEUKIN 6; PREDNISONE; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MONOCYTE; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

ADULT; AGED; FEMALE; HUMANS; INTERLEUKIN-6; MIDDLE AGED; MONOCYTES; SCLERODERMA, SYSTEMIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 0029913252     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Postlethwaite A: Early immune events in scleroderma. Rheum Dis Clin North Am 1990;16:125-40.
2. Famularo G, Procopio A, Giacomelli R, et al: Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis. Clin Exp Immunol 1990;81:368-72.
3. Famularo G, Giacomelli R, Alesse E, et al: Polyclonal B lymphocyte activation in progressive systemic sclerosis. J Clin Lab Immunol 1989;29:59-63.
4. Needleman BW, Wigley FM, Stair RW: Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor α, and interferon-γ levels in sera from patients with scleroderma. Arthritis Rheum 1992;35:67-71.
5. Hirano T; Interleukin-6 and its relation to inflammation and disease. Clin Immunol Immunopathol 1992;62:S60-S65.
6. Varga J, Rosenbloom J, Jimenez SA: Transforming growth factor β (TGF-β) causes a persistent increase in steady state amounts of type I and type HI collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J 1987;247:597-604.
7. Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH: Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor β. J Exp Med 1987;165:251-6.
8. Brown MR, Vaughan J, Jimenez LL, Vale W, Baird A. Transforming growth factor-β: Role in mediating serum-induced endothelin production by vascular endothelial cells. Endocrinology 1991;129:2355-60.
9. LeRoy E, Smith EA, Kahaleh MB, Trojanowska M, Silver RM: A strategy for determining the pathogenesis of systemic sclerosis Is transforming growth factor beta the answer? Arthitis Rheum 1989;32:817-25.
10. Gabriclli A, Di Loreto C, Taborro R, et al: Immunohistochemical localization of intracellular and extracellular associated TGFβ in the skin of patients with systemic sclerosis (scleroderma) and primary Raynaud's phenomenon. Clin Immunol Immunopathol 1993;68:340-9.
11. Sfikakis PP, McCune BK, Tsokos M, Aroni K, Vayiopoulos G, Tsokos GC: Immunohistological demonstration of transforming growth factor-β isoforms in the skin of patients with systemic sclerosis. Clin Immunol Immunopathol 1993;69:199-204.
12. Masi AT, Rodnan GP, Medsger TA, et al: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
13. LeRoy E, Black C, Fleishmajer R, et al: Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
14. Andersson U, Matsuda T: Human interleukin 6 and tumor necrosis factor a production studied at a single-cell level. Eur J Immunol 1989;19:1157-60.
15. Kantor TV, Friberg D, Medsger TA, Buckingham R, Whiteside TL: Cytokine production and serum levels in systemic sclerosis. Clin Immunol Immunopathol 1992;65:278-85.
16. Kovacs EJ: Fibrogenic cytokines: The role of immune mediators in the development of scar tissue. Immunol Today 1991;12:17-23.
17. Smith EA, LeRoy EC: A possible role for transforming growth factor-beta in systemic sclerosis. J Invest Dermatol 1990;95:125S-127S.
18. Pelton BK, Hylton WQ, Denman AM: Activation of IL-6 production by UV irradiation of blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 1992;89:251-4.
19. Dasgupta B, Corkill M, Kirkham B, Gibson T, Panayi G: Serial estimations of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 1992;19:22-5.
20. Yoshizaki K, Matsuda T, Turner M, et al: Pathological significance of interleukin 6 (IL-6/BSF-2) in Castleman's disease. Blood 1989;74:1360-7.
21. Hirano T, Matsuda T, Turner M, et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 1988;18:1797-801.
22. May LT, Viguet H, Kenney JS, Ida N, Allison AC, Seghal PB: High levels of "complexed" interleukin-6 in human blood. J Biol Chem 1992;267:19698-104.
23. Takemura H, Suzuki H, Yoshizaki K, et al: Anti-interleukin-6 autoantibodies in rheumatic diseases. Arthritis Rheum 1992;35:940-3.
24. Roberts AB, Sporn MB, Assoian RK, et al: Transforming growth factor type beta: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986;83:4167-71.
25. Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH: Stimulation of chemotactic migration of human fibroblasts by transforming growth factor-β. J Exp Med 1987;165:251-6.
26. Sasaki H, Pollard RB, Schmid D, Suzuki F: Transforming growth factor-β in the regulation of the immune response. Clin Immunol Immunopathol 1992;65:1-9.
27. Kulozik M, Hogg A, Lankat-Buttgereit B, Kreig T: Colocalization of transforming growth factor beta 2 with alpha 1 (I) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 1990;86:917-22.
28. Kehrl JH, Wakefield LM, Roberts AB, et al: Production of transforming growth factor-β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1980;163-1037-41.
29. Assoian RK, Sporn MB: Type β transforming growth factor in human platelets: Release during degranulation and action on vascular smooth muscle cells. J Cell Biol 1986;102:1211-23.
30. Kahaleh MB, Osborn I, LeRoy EC: Elevated levels of circulating platelets aggregates and beta-thromboglobulin in scleroderma. Ann Intern Med 1982;96:610-3.
31. Gerbracht DD, Steen VD, Ziegler GR, Medsger TA, Rodnan GP: Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease Arthritis Rheum 1955,28:87-92.
32. Harper FE, Maricq HR, Turner RE, Lidman RW, LeRoy EC: A prospective study of Raynaud's phenomenon and early connective tissue disease: A five-year report. Am J Med 1982;12:883-8
33. Vuorio T, Kahari B, Black C, Vuorio E: Expression of osteonectin, decorin and transforming growth factor-β1 genes in fibroblasts cultured from patients with systemic sclerosis and morphca J Rheumatol 1991;19:51-8.
34. Connor TB, Roberts AB, Sporn MB, et al: Correlation of fibrosis and transforming growth factor-β type 2 levels in the eye. J Clin Invest 1989;83:1661-6.